August 2022 TAS2R supports odontoblastic differentiation of human dental pulp stem cells in the inflammatory microenvironment " Background: Inflammatory microenvironment promotes odontoblastic differentiation this study, we aimed to explore the role of TAS2R in odontoblastic differentiation of hDPSCs in the inflammatory Methods: Microarray analysis was performed to explore the differential mRNA profiles in inflammatory

GRK2/β-arrestin2 play multiple roles in the pathological mechanisms of a wide range of diseases including heart failure, cancer, and inflammatory diseases. in immune cell function and focuses on the pathological implications of GRK2/β-arrestin2 in various inflammatory diseases."

The fact that GPR84 expression in leukocytes is remarkably increased under acute inflammatory stimuli such as lipopolysaccharide (LPS) and TNFα suggests that it may play a role in the development of inflammatory and fibrotic diseases. GPR84 activation imposes pro-inflammatory properties in colonic macrophages through enhancing NLRP3 inflammasome GPR84 antagonist discovered by us, suppresses colitis by reducing the polarization and function of pro-inflammatory

diseases and cancers Published date March 15, 2023 Abstract " C-X-C motif chemokine receptor 2 (CXCR2 ) is G protein-coupled receptor (GPCR) and plays important roles in various inflammatory diseases and cancers, including chronic obstructive pulmonary disease (COPD), atherosclerosis, asthma, and pancreatic diseases and cancers. (COPD) , Coronavirus disease 2019 (COVID-19) , Inflammatory disease.

the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for metabolic diseases including Type 2 Diabetes and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing new treatments for malaria.

, our findings propose a therapeutic potential in combined CXCR4 and LPA1 inhibitors for cancer and inflammatory diseases associated with these receptors, simultaneously raising concerns about the use of LPA1 antagonists Chemokine receptor 4 , Chemotaxis , G protein-coupled receptor , GPCR heteromer , GPCR signaling , Inflammatory disease , Lysophosphatidic acid receptor 1 Source Contribute to the GPCR News Coming soon Become a Contributor